TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25401325
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin 100 mg/d
Study: 22833639
Drug: Posaconazole tablet
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole tablet 200 mg once daily
Study: 22833639
Drug: Posaconazole tablet
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole tablet 200 mg twice daily
Study: 22833639
Drug: Posaconazole tablet
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole tablet 400 mg once daily
Study: 17767075
Drug: Aprotinin (10,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (10,000 KIU test dose, 2 million KIU load, 0.5 million KIU per hour)
Study: 15164290
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of different tests
Study: 9696955
Drug: Caffeine (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (4.5 mg. 1(‐1) and 9 mg. 1(‐1))
Study: 9696955
Drug: Theophylline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (3 mg. 1(‐1), 6 mg. 1(‐1), and 12 mg. 1(‐1))
Study: 9696955
Drug: Caffeine and
Normalized name: caffeine and sodium benzoate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine and Theophylline (all doses)
Study: 7511070
Drug: Farmorubicin (FARM)
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Farmorubicin (FARM) at a dose of 72 mg/body
Study: 7511070
Drug: Adriamycin (ADR)
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin (ADR) at a dose of 48 mg/body
Study: 3947524
Drug: Nebulizer therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulizer therapy with salbutamol (1 mg in 2 ml of physiological saline) driven by piped oxygen at 8 litres/min
Study: 3947524
Drug: Nebulizer therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulizer therapy with salbutamol (1 mg in 2 ml of physiological saline) driven by piped oxygen at 6 litres/min
Study: 3947524
Drug: Nebulizer therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulizer therapy with salbutamol (1 mg in 2 ml of physiological saline) driven by piped oxygen at 4 litres/min
Study: 29114907
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (5 mg) intravenous infusion at day 0 and at 12 months
Study: 20302588
Drug: 1-week quadruple
Normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-week quadruple therapy (tripotassium dicitrate bismuthate 300 mg q.i.d., metronidazole 500 mg t.i.d., tetracycline 500 mg q.i.d., esomeprazole 20 mg b.i.d.)
Study: 20302588
Drug: 2-week quadruple
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week quadruple therapy (tripotassium dicitrate bismuthate 300 mg q.i.d., metronidazole 500 mg t.i.d., tetracycline 500 mg q.i.d., esomeprazole 20 mg b.i.d.)
Study: 20302588
Drug: 1-week quadruple
Normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-week quadruple therapy
Study: 20302588
Drug: 2-week quadruple
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week quadruple therapy
Study: 9411543
Drug: Drug-free regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free regimen
Study: 9411543
Drug: Liver necrosis
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liver necrosis index (for drug-free regimen)
Study: 30958831
Drug: SCBSCT‐BA (Cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCBSCT‐BA (Cognitive-behavioral smoking cessation treatment with behavioral activation)
Study: 30958831
Drug: SCBSCT (Standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCBSCT (Standard cognitive-behavioral treatment)
Study: 30256095
Drug: Combined water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined water treatment, sanitation, handwashing (WSH)
Study: 25294886
Drug: FOLFOX ±
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX ± cetuximab therapy
Study: 19606688
Drug: Follow-up ultrasound
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up ultrasound evaluation after successful treatment of basic diseases
Study: 11564001
Drug: Buspirone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (30 mg)
Study: 11573063
Drug: Glucose 33%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose 33% solution
Study: 11573063
Drug: Glucose 5%
Normalized name: Glucose 5% Nursette
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose 5% solution
Study: 8113846
Drug: Sequential treatment:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment: cisplatin 100 mg/m2 over 15 minutes on day 1 plus 5‐FU 1.0 g/m2 by continuous infusion on days 1 to 5, followed by 70 Gy of radiation in 7 to 8 weeks.
Study: 8113846
Drug: Concomitant treatment:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant treatment: cisplatin 60 mg/m2 over 15 minutes on day 1 plus 5‐FU 800 mg/m2 by continuous infusion on days 1 to 5 plus radiation 2 Gy on days 1 to 5, repeated every other week for seven cycles.
Study: 27134145
Drug: Concomitant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant treatment
Study: 8113846
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment and Concomitant treatment
Study: 26059709
Drug: 0·9% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0·9% sodium chloride sterile solution
Study: 25680887
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker (CCB) group: losartan 50 mg plus amlodipine 5 mg
Study: 25680887
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor (ACEI) group: enalapril 5 mg
Study: 25680887
Drug: Thiazide diuretic
Normalized name: Thiazide diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide diuretic (HCTZ) group: hydrochlorothiazide 12.5 mg
Study: 25680887
Drug: Control period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control period (usual dose of ARB)
Study: 23966328
Drug: Low-fat milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat milk (475 mL)
Study: 21910712
Drug: 1450 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1450 nm laser treatment (Candela Smoothbeam laser); 3 treatments performed monthly, using a double-pass technique, 6 mm spot size, 210 ms pulse duration, fluence of 8 or 9 J cm(‐2)
Study: 21910712
Drug: 1450 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1450 nm laser treatment
Study: 18939389
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (hemoglobin A1c target 7.0% to 7.9%)
Study: 17023867
Drug: Immediate-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release methylphenidate (MPH-IR) at 2.5 mg t.i.d.
Study: 17023867
Drug: Immediate-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release methylphenidate (MPH-IR) at 5 mg t.i.d.
Study: 17023867
Drug: Immediate-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release methylphenidate (MPH-IR) at 7.5 mg t.i.d.
Study: 17023867
Drug: Best-dose MPH
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Best-dose MPH
Study: 10079408
Drug: Intracytoplasmic sperm
Normalized name: herring sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracytoplasmic sperm injection (ICSI) (n = 126 oocytes)
Study: 7307036
Drug: Miconazole tampons
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miconazole tampons (2 tampons daily for 5 days)
Study: 7307036
Drug: Clotrimazole vaginal
Normalized name: Clotrimazole Vaginal Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole vaginal tablets (1 tablet daily for 6 days)
Study: 30902692
Drug: Bacterial keratitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacterial keratitis treatment
Study: 15182379
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care provided by community pharmacists after training
Study: 9400878
Drug: Consultation-liaison psychiatry
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Consultation-liaison psychiatry service (C-L) referrals without symptom-matched controls (n = 27)
Study: 9400878
Drug: Symptom-matched C-L
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom-matched C-L referrals
Study: 9808859
Drug: Sublingual glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual glyceryl trinitrate (GTN)
Study: 7622910
Drug: IL-1 receptor
Normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-1 receptor antagonist (IL-1ra)
Study: 22777396
Drug: Emotional demands
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emotional demands (unfair treatment, client's family abuse)
Study: 21710402
Drug: yohimbine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: yohimbine (0.4 mg/kg)
Study: 15529514
Drug: Metformin-glibenclamide combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin-glibenclamide combination tablets (Glucovance)
Study: 2851443
Drug: CEP/MEC chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEP/MEC chemotherapy (cyclophosphamide 500 mg/m2 i.v. day 1; epirubicin 50 mg/m2 i.v. day 1; cisplatin 80 mg/m2 i.v. day 1; alternated with methotrexate 30 mg/m2 i.v. day 1; etoposide 200 mg/m2 i.v. day 1; CCNU 70 mg/m2 per os, day 1) until progression.
Study: 30921804
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy (SCIT) with house dust mite extract
Study: 28673214
Drug: TAP catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP catheter (18 ml 0.5% ropivacaine every four hours)
Study: 28673214
Drug: PRS catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRS catheter (18 ml 0.5% ropivacaine every four hours)
Study: 28673214
Drug: SC catheter
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC catheter (18 ml 0.5% ropivacaine every four hours)
Study: 21255767
Drug: 10‐week web‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐week web‐based unguided self‐help treatment for social phobia
Study: 21255767
Drug: 10‐week web‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐week web‐based self‐help treatment with minimal weekly therapist support via email
Study: 21255767
Drug: 10‐week web‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐week web‐based self‐help treatment with flexibly stepped-up support (email or telephone contact on demand)
Study: 19298412
Drug: prulifloxacin 600
Normalized name: Orbifloxacin
DrugBank: Orbifloxacin (DB11443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: prulifloxacin 600 mg
Study: 12765806
Drug: Heparin (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (5000 units every 12 hours, SC, for 7 days)
Study: 10983362
Drug: Amitriptyline (12.5-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (12.5-25 mg/daily)
Study: 10983362
Drug: Fluoxetine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (10-20 mg/daily)
Study: 10983362
Drug: Maprotiline (10-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline (10-25 mg/daily)
Study: 9313603
Drug: Mibefradil 6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibefradil 6.25 mg, 12.5 mg, 25 mg, 50 mg, 100 mg
Study: 8383396
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment based on ambulatory monitoring
Study: 8383396
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment based on conventional sphygmomanometry
Study: 31591117
Drug: Early Bayesian
Normalized name: Babesia microti preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early Bayesian dose adjustment of vancomycin
Study: 25714534
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine gel (Group Gel)
Study: 17339157
Drug: 7.5 mL
Normalized name: 7.5 ML Spevigo 60 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mL autologous blood
Study: 17339157
Drug: 15 mL
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL autologous blood
Study: 2089087
Drug: Moclobemide (300-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (300-600 mg/d)
Study: 2089087
Drug: Imipramine (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (100-200 mg/d)
Study: 30117365
Drug: BCAA (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA (20 g/day)
Study: 30117365
Drug: Omega-3 (2,700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 (2,700 mg/day)
Study: 24113764
Drug: Treatment-as-usual control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual control condition
Study: 9740261
Drug: Artemether 300
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artemether 300 mg plus Pyrimethamine 100 mg
Study: 9740261
Drug: Artemether 300
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artemether 300 mg
Study: 9740261
Drug: Pyrimethamine 100
Normalized name: pyrimethamine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrimethamine 100 mg
Study: 23607501
Drug: TAFF (Separation
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAFF (Separation Anxiety Family Therapy)
Study: 23607501
Drug: CC (Coping
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC (Coping Cat)
Study: 23607501
Drug: Both TAFF
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both TAFF and CC
Study: 21479682
Drug: Sivelestat administered
Normalized name: Sivelestat
DrugBank: Sivelestat (DB12863)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Sivelestat administered until postoperative day (POD) 2 (Group A)
Study: 21479682
Drug: Sivelestat administered
Normalized name: Sivelestat
DrugBank: Sivelestat (DB12863)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Sivelestat administered until postoperative day (POD) 5 (Group B)
Study: 21479682
Drug: Historical controls
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical controls without Sivelestat administration
Study: 19783715
Drug: Phentermine 15
Normalized name: phentermine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentermine 15 mg with Taranabant 0.5 mg
Study: 19783715
Drug: Phentermine 15
Normalized name: phentermine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentermine 15 mg with Taranabant 2 mg
Study: 19783715
Drug: Phentermine 15
Normalized name: phentermine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentermine 15 mg without Taranabant
Study: 19783715
Drug: Phentermine 15
Normalized name: phentermine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentermine 15 mg with Taranabant 1 mg
Study: 16981054
Drug: Transport with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transport with platelet GP IIb/IIIa receptor inhibitor (tirofiban; 10 mg/kg IV bolus followed by 0.1 mg/kg/min infusion during transport)
Study: 9038856
Drug: Regular human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin at 2.0 mU.kg‐1.min‐1
Study: 9038856
Drug: Regular human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin at 4.0 mU.kg‐1.min‐1
Study: 8587082
Drug: Nabumetone 1000-1500
Normalized name: nabumetone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone 1000-1500 mg po daily
Study: 8587082
Drug: Diclofenac SR
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac SR 100-150 mg po daily
Study: 23596006
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of bone marrow-derived mononuclear cells (BM-MNC) early (5 to 7 days after MI)
Study: 23596006
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of bone marrow-derived mononuclear cells (BM-MNC) late (3 to 4 weeks after MI)
Study: 22833405
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no BM-MNC treatment)
Study: 20143531
Drug: Bevacizumab (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (1.25 mg administered into the vitreous body)
Study: 17117128
Drug: Non-goal-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-goal-directed therapy
Study: 11342894
Drug: Crushed tablets
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed tablets
Study: 11342894
Drug: Chewed tablets
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewed tablets
Study: 11342894
Drug: Whole tablets
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole tablets
Study: 1833301
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg DHAS i.v. administration
Study: 6623364
Drug: CPAP/IMV (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP/IMV (high tidal volumes 12 to 18 ml/kg)
Study: 6623364
Drug: ZEEP/A-CM (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZEEP/A-CM (low tidal volumes 8 to 10 ml/kg)
Study: 28174353
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg daily for 30 days
Study: 22854880
Drug: Cocoa beverages
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa beverages (30-900 mg flavanol per day)
Study: 18634706
Drug: 6-week herring
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-week herring diet (150 g baked herring fillets/d, 5 d/week)
Study: 18634706
Drug: Reference diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference diet (150 g baked lean pork and chicken fillets/d, 5 d/week)
Study: 17961422
Drug: Pravastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (20 mg/d on top of standard therapy)
Study: 9824387
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (1600 microg/day)
Study: 9824387
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (1600 microg/day) plus oral prednisolone (5 mg/day)
Study: 7650226
Drug: 80-mg immediate-release
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80-mg immediate-release (IR) tablet, phase A
Study: 7650226
Drug: Two 80-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 80-mg IR tablets, phase B
Study: 7650226
Drug: 160-mg controlled-release
Normalized name: Betadur CR 160 MG Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160-mg controlled-release capsule, phase C
Study: 7650226
Drug: 10-mg IV
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-mg IV bolus, phase D
Study: 2192716
Drug: Dispersible tablets
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible tablets (2 X 150 mg)
Study: 2192716
Drug: Film-coated tablets
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Film-coated tablets (2 X 150 mg)
Study: 422304
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of propranolol and dihydrallazine
Study: 28411506
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy followed by PEP (CBT+PEP)
Study: 25256567
Drug: Standard hemodiafiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hemodiafiltration (HDF) with bicarbonate (34 mmol/L) and acetate dialysate (3 mmol/L)
Study: 21857144
Drug: Triple antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiplatelet therapy (TAT; addition of cilostazol to dual antiplatelet therapy)
Study: 29773949
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAT)
Study: 17503066
Drug: Antibiotic ointment
Normalized name: CVS Antibiotic Ointment
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic ointment with hydrocortisone acetate (AB + HC)
Study: 17503066
Drug: Antibiotic ointment
Normalized name: CVS Antibiotic Ointment
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic ointment (AB)
Study: 15025615
Drug: Ketamine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.4 mg kg(‐1)
Study: 15025615
Drug: Lidocaine 2.5
Normalized name: LIDOCAINE 2.5% OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2.5 mg kg(‐1)
Study: 9161392
Drug: DVT prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DVT prophylaxis using low-dose heparin sodium therapy (5000 U every 12 hours) and calf-length intermittent mechanical compression devices